{"id":"raltegravir-isentress","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Elevated creatine kinase"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the catalytic activity of HIV integrase, the enzyme responsible for inserting viral DNA into the human genome. By preventing this integration step, the drug blocks HIV replication and reduces viral load in infected individuals. This mechanism is distinct from reverse transcriptase or protease inhibitors and represents a newer class of antiretroviral therapy.","oneSentence":"Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:20.497Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in pediatric patients"}]},"trialDetails":[{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT04024150","phase":"","title":"Pregnancy, Anti-integrase and Lymphocyte Repertoire of the Newborn","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-04","conditions":"Anti-integrases","enrollment":29},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT05642481","phase":"","title":"Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT03194165","phase":"","title":"Population Pharmacokinetics of Antiretroviral in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-16","conditions":"Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed","enrollment":65},{"nctId":"NCT01234116","phase":"PHASE4","title":"Post-Exposure Prophylaxis in Health Care Workers","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2011-02","conditions":"Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT03311945","phase":"PHASE3","title":"Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2018-05-02","conditions":"HIV Infections, HIV-1-infection, HIV Seropositivity","enrollment":33},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT01513122","phase":"PHASE4","title":"Bone and Body Comp: A Sub Study of the SECOND-LINE Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2010-02","conditions":"HIV","enrollment":210},{"nctId":"NCT03029689","phase":"PHASE3","title":"Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2017-07-28","conditions":"HIV","enrollment":61},{"nctId":"NCT03333083","phase":"PHASE3","title":"Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen","status":"TERMINATED","sponsor":"Judit Pich","startDate":"2018-05-03","conditions":"HIV Seropositivity, HIV Infections, HIV-1-infection","enrollment":17},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT04513626","phase":"PHASE2","title":"HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label","status":"RECRUITING","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2020-09-15","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT02691065","phase":"PHASE4","title":"Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2017-01-20","conditions":"HIV","enrollment":6},{"nctId":"NCT01854762","phase":"PHASE2, PHASE3","title":"Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection","status":"TERMINATED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2015-06-01","conditions":"HIV, Pregnancy","enrollment":33},{"nctId":"NCT01059422","phase":"PHASE4","title":"Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients","status":"COMPLETED","sponsor":"Central Institute of Epidemiology, Moscow, Russia","startDate":"2010-10","conditions":"HIV Infections, Tuberculosis","enrollment":10},{"nctId":"NCT03174977","phase":"EARLY_PHASE1","title":"Pharmacokinetics Distribution of Raltegravir by PET/MR","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2018-04-01","conditions":"HIV-1-infection","enrollment":10},{"nctId":"NCT01480713","phase":"PHASE3","title":"Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2012-05","conditions":"HIV-1 Infection","enrollment":41},{"nctId":"NCT01712425","phase":"PHASE1","title":"Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2012-10","conditions":"HIV","enrollment":48},{"nctId":"NCT01251601","phase":"","title":"The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-11","conditions":"HIV, Pregnancy","enrollment":""},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT02708342","phase":"","title":"Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2016-04","conditions":"HIV","enrollment":100},{"nctId":"NCT04258475","phase":"PHASE4","title":"The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2020-12-09","conditions":"Calcium Supplementation in HIV Patients Using Raltegravir","enrollment":12},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT02210715","phase":"PHASE4","title":"Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-03","conditions":"HIV, Fatty Liver, Nonalcoholic Steatohepatitis","enrollment":31},{"nctId":"NCT04460924","phase":"","title":"ARTiBIOME: Observational Study on the Effect of HIV and ART on Gut Microbiome","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2020-11-01","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT05648201","phase":"PHASE4","title":"Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"Hiv","enrollment":36},{"nctId":"NCT01867320","phase":"EARLY_PHASE1","title":"Raltegravir for HAM/TSP","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2013-09-05","conditions":"HTLV-I Infection","enrollment":19},{"nctId":"NCT05751031","phase":"","title":"Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)","status":"UNKNOWN","sponsor":"Fondazione Penta UK","startDate":"2023-02-20","conditions":"HIV Infections","enrollment":1200},{"nctId":"NCT03332095","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT03579485","phase":"","title":"An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients.(RalAge)","status":"UNKNOWN","sponsor":"Azienda Policlinico Umberto I","startDate":"2018-01-31","conditions":"Hiv","enrollment":90},{"nctId":"NCT01204905","phase":"NA","title":"R5 Integrase Study in HIV-1 Naive Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-09","conditions":"HIV Infections","enrollment":7},{"nctId":"NCT00594646","phase":"PHASE4","title":"HIV Non Occupational Post-Exposure Prophylaxis (PEP)","status":"COMPLETED","sponsor":"Fenway Community Health","startDate":"2008-02","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT04901728","phase":"","title":"Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)","status":"UNKNOWN","sponsor":"University of Sussex","startDate":"2021-07-01","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT01231516","phase":"PHASE3","title":"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-26","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":724},{"nctId":"NCT04887675","phase":"NA","title":"Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI","status":"UNKNOWN","sponsor":"University of Novi Sad","startDate":"2021-05-01","conditions":"HIV I Infection, HIV Associated Lipodystrophy, Metabolic Syndrome","enrollment":120},{"nctId":"NCT01828073","phase":"","title":"Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-05-19","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01780831","phase":"PHASE1","title":"Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-28","conditions":"HIV Infections","enrollment":52},{"nctId":"NCT01751568","phase":"PHASE1, PHASE2","title":"Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-11-12","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT00515827","phase":"PHASE2","title":"Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT00485264","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-09-17","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT00660972","phase":"PHASE1","title":"Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00852618","phase":"","title":"Intensive Viral Dynamics Substudy of A5248","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Treatment Naive","enrollment":11},{"nctId":"NCT01896921","phase":"PHASE3","title":"Switch to Maraviroc + Integrase Inhibitor","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2013-09","conditions":"HIV","enrollment":7},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03374358","phase":"PHASE4","title":"Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2018-01-10","conditions":"HIV Seropositivity, Metabolic Syndrome, Fatty Liver","enrollment":45},{"nctId":"NCT01147107","phase":"PHASE4","title":"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2014-02","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":80},{"nctId":"NCT04051970","phase":"PHASE3","title":"Reducing Antiretroviral Treatments","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2019-11-27","conditions":"HIV-1-infection","enrollment":360},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT02611895","phase":"NA","title":"Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-03","conditions":"HIV-1 Infection","enrollment":120},{"nctId":"NCT02212379","phase":"PHASE2","title":"Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-01","conditions":"HIV-1 Infection","enrollment":170},{"nctId":"NCT03060447","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-05-09","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT03205566","phase":"PHASE4","title":"Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2017-09-19","conditions":"Hiv","enrollment":38},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT00738569","phase":"NA","title":"Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2008-07","conditions":"HIV","enrollment":30},{"nctId":"NCT01288417","phase":"PHASE1","title":"Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2011-08","conditions":"HIV Infections, HCV Infections","enrollment":24},{"nctId":"NCT01246804","phase":"PHASE1","title":"The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-11","conditions":"HIV Infections, Depression, Mild Cognitive Impairment","enrollment":18},{"nctId":"NCT00943540","phase":"PHASE2","title":"Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-07","conditions":"HIV Infection, HIV Infections","enrollment":20},{"nctId":"NCT02577042","phase":"PHASE4","title":"Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2015-10-15","conditions":"Aging-related Inflammation in HIV-infected Patients","enrollment":42},{"nctId":"NCT01779687","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-03","conditions":"HIV, Hypercholesterolaemia","enrollment":24},{"nctId":"NCT00618241","phase":"PHASE1","title":"Pharmacokinetic Study on Raltegravir and Lamotrigine","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-02","conditions":"HIV Infection","enrollment":24},{"nctId":"NCT00665717","phase":"PHASE1","title":"The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-05","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01978782","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-01","conditions":"HIV, Depression","enrollment":24},{"nctId":"NCT00631449","phase":"PHASE4","title":"Raltegravir Intensification in HIV-infected Patients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-02","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT01159132","phase":"PHASE2","title":"Pharmacokinetics of Low Dose Raltegravir","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01025427","phase":"PHASE4","title":"HIV Persistence and Viral Reservoirs","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12","conditions":"HIV, HIV Infections","enrollment":16},{"nctId":"NCT03369743","phase":"","title":"Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD)","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2018-01-02","conditions":"HIV Infections","enrollment":125},{"nctId":"NCT03195452","phase":"PHASE2","title":"QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2017-11-08","conditions":"Virus-HIV","enrollment":100},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02858401","phase":"PHASE1","title":"Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-29","conditions":"HIV-1 Infection","enrollment":48},{"nctId":"NCT02995824","phase":"","title":"Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2002-01","conditions":"Liver Transplantation, HIV Infections, Antiretroviral Therapy","enrollment":271},{"nctId":"NCT00808002","phase":"PHASE3","title":"Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-02","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01618305","phase":"PHASE4","title":"Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission","status":"COMPLETED","sponsor":"Westat","startDate":"2013-09-05","conditions":"HIV Infections","enrollment":408},{"nctId":"NCT00995241","phase":"PHASE4","title":"Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-11","conditions":"HIV Infections","enrollment":5},{"nctId":"NCT00718536","phase":"PHASE4","title":"Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-08","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00685191","phase":"PHASE4","title":"HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-06","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00554398","phase":"PHASE3","title":"Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2007-11","conditions":"HIV Infections","enrollment":69},{"nctId":"NCT01078233","phase":"","title":"Observational Data Analysis in EuroSIDA (MK-0518-058)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05-05","conditions":"HIV-1 Infections","enrollment":6617},{"nctId":"NCT01335620","phase":"PHASE4","title":"The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-04","conditions":"HIV","enrollment":19},{"nctId":"NCT01293123","phase":"NA","title":"Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2011-12","conditions":"HIV","enrollment":2},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT00982553","phase":"PHASE1","title":"The Raltegravir and Ribavirin Pharmacokinetics (PK) Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2009-09","conditions":"HIV Infections","enrollment":14}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"MATERNAL DRUGS AFFECTING FOETUS"},{"count":3,"reaction":"VOLVULUS"},{"count":2,"reaction":"TRISOMY 21"},{"count":1,"reaction":"ABORTION"},{"count":1,"reaction":"ABORTION INDUCED"},{"count":1,"reaction":"BACTERIAL TEST POSITIVE"},{"count":1,"reaction":"CELLULITIS"},{"count":1,"reaction":"CONGENITAL ANOMALY"},{"count":1,"reaction":"DEVICE FAILURE"},{"count":1,"reaction":"DYSPHAGIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ISENTRESS","MK-0518"],"phase":"phase_3","status":"active","brandName":"raltegravir (Isentress)","genericName":"raltegravir (Isentress)","companyName":"Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux","companyId":"groupe-d-etude-sur-le-risque-d-exposition-des-soignants-aux-agents-infectieux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}